NCT06932367 - The Efficacy of Dexketoprofen And Methylprednisolone in the Acute Low Back Pain | Biotech Hunter

Enrollment

150

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

August 1, 2022

Study Completion Date

January 2, 2025

Conditions

Low Back Pain

Interventions

DRUG

Dexketoprofen (KETAVEL 50 mg/2 ml)

Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.

COMBINATION_PRODUCT

Methylprednisolone (Corticosteroid)

Patients with low back pain were divided in to two groups: those receiving intravenous dexketoprofen treatment (Group 1) and those receiving dexketoprofen + methylprednisolone treatment (Group 2). The efficacy of the treatments received by the patients was evaluated with the VAS at minutes 0, 15, 30, and 60 and hour 48. Statistical evaluations were also undertaken on the ODI results evaluated at minute 0 and hour 48.

Trial Locations (1)

25100

Ataturk University, Erzurum